Recombinational DNA repair and human disease

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 509, Issue 1-2, 2002, Pages 49-78

  Thompson, Larry H ^a   Schild, David ^b  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Ataxia telangiectasia; Bloom syndrome; BRCA1; BRCA2; Chromosomal instability; Fanconi anemia; Werner syndrome

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; DOUBLE STRANDED DNA; HELICASE; RAD51 PROTEIN; REACTIVE OXYGEN METABOLITE;

ATAXIA TELANGIECTASIA; BLOOM SYNDROME; BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CELL FUNCTION; CELL LINE; CHROMOSOME ABERRATION; CHROMOSOME SEGREGATION; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DNA TRANSCRIPTION; FANCONI ANEMIA; GENE MUTATION; GENE TARGETING; GENETIC DISORDER; HOMOLOGOUS RECOMBINATION; HUMAN; IONIZING RADIATION; KARYOTYPE; NIJMEGEN BREAKAGE SYNDROME; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; REGULATORY MECHANISM; REVIEW; ROTHMUND THOMSON SYNDROME; SIGNAL TRANSDUCTION; SISTER CHROMATID EXCHANGE; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; WERNER SYNDROME;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0037202608     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(02)00224-5     Document Type: Article

References (379)

1. Nanjangud G., Rao P.H., Hegde A., Teruya-Feldstein J., Donnelly G., Qin J., Jhanwar S.C., Zelenetz A.D., Chaganti R.S. Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. Blood. 99:2002;2554-2561.
2. Haber J.E. Partners and pathways repairing a double-strand break. Trends Genet. 16:2000;259-264.
3. Barnes D.E. Non-homologous end joining as a mechanism of DNA repair. Curr. Biol. 11:2001;R455-R457.
4. Pierce A.J., Jasin M. NHEJ deficiency and disease. Mol. Cell. 8:2001;1160-1161.
5. Thompson L.H., Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res. 477:2001;131-153.
6. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27:2001;247-254.
7. Jackson S.P. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 23:2002;687-696.
8. Ferguson D.O., Alt F.W. DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene. 20:2001;5572-5579.
9. Gatti R.A. The inherited basis of human radiosensitivity. Acta Oncol. 40:2001;702-711.
10. Liang F., Han M., Romaniekno P.J., Jasin M. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;5172-5177.
11. Bailey S.M., Meyne J., Chen D.J., Kurimasa A., Li G.C., Lehnert B.E., Goodwin E.H. DNA double-strand break repair proteins are required to cap the ends of mammalian chromosomes. Proc. Natl. Acad. Sci. U.S.A. 96:1999;14899-14904.
12. Goytisolo F.A., Samper E., Edmonson S., Taccioli G.E., Blasco M.A. The absence of the DNA-dependent protein kinase catalytic subunit in mice results in anaphase bridges and in increased telomeric fusions with normal telomere length and G-strand overhang. Mol. Cell. Biol. 21:2001;3642-3651.
13. Gilley D., Tanaka H., Hande M.P., Kurimasa A., Li G.C., Oshimura M., Chen D.J. DNA-PKcs is critical for telomere capping. Proc. Natl. Acad. Sci. U.S.A. 98:2001;15084-15088.
14. d'Adda di Fagagna F., Hande M.P., Tong W., Roth D., Lansdorp P.M., Wang Z., Jackson S.P. Effects of DNA nonhomologous end-joining factors on telomere length and chromosomal stability in mammalian cells. Curr. Biol. 11:2001;1192-1196.
15. Karanjawala Z.E., Grawunder U., Hsieh C.L., Lieber M.R. The nonhomologous DNA end joining pathway is important for chromosome stability in primary fibroblasts. Curr. Biol. 9:1999;1501-1504.
16. Difilippantonio M.J., Zhu J., Chen H.T., Meffre E., Nussenzweig M.C., Max E.E., Ried T., Nussenzweig A. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature. 404:2000;510-514.
17. Ferguson D.O., Sekiguchi J.M., Chang S., Frank K.M., Gao Y., DePinho R.A., Alt F.W. The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6630-6633.
18. Grawunder U., Harfst E. How to make ends meet in V(D)J recombination. Curr. Opin. Immunol. 13:2001;186-194.
19. Thompson L.H., Schild D. The contribution of homologous recombination in preserving genome integrity in mammalian cells. Biochimie. 81:1999;87-105.
20. Thacker J. The role of homologous recombination processes in the repair of severe forms of DNA damage in mammalian cells. Biochimie. 81:1999;77-85.
21. Meyn M.S. Chromosome instability syndromes: lessons for carcinogenesis. Curr. Top. Microbiol. Immunol. 221:1997;71-148.
22. Spring K., Cross S., Li C., Watters D., Ben-Senior L., Waring P., Ahangari F., Lu S.L., Chen P., Misko I., Paterson C., Kay G., Smorodinsky N.I., Shiloh Y., Lavin M.F. Atm knock-in mice harboring an in-frame deletion corresponding to the human ATM 7636de19 common mutation exhibit a variant phenotype. Cancer Res. 61:2001;4561-4568.
23. Lavin M.F., Khanna K.K. ATM: the protein encoded by the gene mutated in the radiosensitive syndrome ataxia-telangiectasia. Int. J. Radiat. Biol. 75:1999;1201-1214.
24. Shiloh Y., Kastan M.B. ATM: genome stability, neuronal development, and cancer cross paths. Adv. Cancer Res. 83:2001;209-254.
25. Khanna K.K., Lavin M.F., Jackson S.P., Mulhern T.D. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ. 8:2001;1052-1065.
26. Pandita T.K. ATM function and telomere stability. Oncogene. 21:2002;611-618.
27. Taylor A.M., Harnden D.G., Arlett C.F., Harcourt S.A., Lehmann A.R., Stevens S., Bridges B.A. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature. 258:1975;427-429.
28. Thacker J. Inherited sensitivity to X-rays in man. Bioessays. 11:1989;58-62.
29. Bigbee W.L., Langlois R.G., Swift M., Jensen R.H. Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia. Am. J. Hum. Genet. 44:1989;402-408.
30. Cole J., Arlett C.F. Cloning efficiency and spontaneous mutant frequency in circulating T-lymphocytes in ataxia-telangiectasia patients. Int. J. Radiat. Biol. 66:1994;S123-S131.
31. Blocher D., Sigut D., Hannan M.A. Fibroblasts from ataxia telangiectasia (AT) and AT heterozygotes show an enhanced level of residual DNA double-strand breaks after low dose-rate gamma-irradiation as assayed by pulsed field gel electrophoresis. Int. J. Radiat. Biol. 60:1991;791-802.
32. Cornforth M.N., Bedford J.S. On the nature of a defect in cells from individuals with ataxia-telangiectasia. Science. 227:1985;1589-1591.
33. Foray N., Priestley A., Alsbeih G., Badie C., Capulas E.P., Arlett C.F., Malaise E.P. Hypersensitivity of ataxia telangiectasia fibroblasts to ionizing radiation is associated with a repair deficiency of DNA double-strand breaks. Int. J. Radiat. Biol. 72:1997;271-283.
34. Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., Shiloh Y., Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet. 4:1995;2025-2032.
35. Lavin M.F., Khanna K.K., Beamish H., Spring K., Watters D., Shiloh Y. Relationship of the ataxiatelangiectasia protein ATM to phosphoinositide 3-kinase. Trends Biochem. Sci. 20:1995;382-383.
36. Watters D., Kedar P., Spring K., Bjorkman J., Chen P., Gatei M., Birrell G., Garrone B., Srinivasa P., Crane D.I., Lavin M.F. Localization of a portion of extranuclear ATM to peroxisomes. J. Biol. Chem. 274:1999;34277-34282.
37. Barlow C., Ribaut-Barassin C., Zwingman T.A., Pope A.J., Brown K.D., Owens J.W., Larson D., Harrington E.A., Haeberle A.M., Mariani J., Eckhaus M., Herrup K., Bailly Y., Wynshaw-Boris A. ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;871-876.
38. Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y., Tagle D.A. The ataxiatelangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage. Proc. Natl. Acad. Sci. U.S.A. 94:1997;1840-1845.
39. Rotman G., Shiloh Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene. 18:1999;6135-6144.
40. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 11:2001;71-77.
41. Theodosiou A., Smith A., Gillieron C., Arkinstall S., Ashworth A. MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene. 18:1999;6981-6988.
42. Bar-Shira A., Rashi-Elkeles S., Zlochover L., Moyal L., Smorodinsky N.I., Seger R., Shiloh Y. ATM-dependent activation of the gene encoding MAP kinase phosphatase 5 by radiomimetic DNA damage. Oncogene. 21:2002;849-855.
43. Waterman M.J., Stavridi E.S., Waterman J.L., Halazonetis T.D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19:1998;175-178.
44. Bentley N.J., Holtzman D.A., Flaggs G., Keegan K.S., DeMaggio A., Ford J.C., Hoekstra M., Carr A.M. The Schizosaccharomyces pombe rad3 checkpoint gene. EMBO J. 15:1996;6641-6651.
45. Brown E.J., Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14:2000;397-402.
46. de Klein A., Muijtjens M., van Os R., Verhoeven Y., Smit B., Carr A.M., Lehmann A.R., Hoeijmakers J.H. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr. Biol. 10:2000;479-482.
47. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2001;2177-2196.
48. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273:1998;5858-5868.
49. Rogakou E.P., Boon C., Redon C., Bonner W.M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell. Biol. 146:1999;905-916.
50. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 10:2000;886-895.
51. Burma S., Chen B.P., Murphy M., Kurimasa A., Chen D.J. ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks. J. Biol. Chem. 276:2001;42462-42467.
52. Andegeko Y., Moyal L., Mitelman L., Tsarfaty I., Shiloh Y., Rotman G. Nuclear retention of ATM at sites of DNA double strand breaks. J. Biol. Chem. 276:2001;38224-38230.
53. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677.
54. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
55. Scott S.P., Bendix R., Chen P., Clark R., Dork T., Lavin M.F. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc. Natl. Acad. Sci. U.S.A. 99:2002;925-930.
56. Celeste A., Petersen S., Romanienko P.J., Fernandez-Capetillo O., Chen H.T., Sedelnikova O.A., Reina-San-Martin B., Coppola V., Meffre E., Difilippantonio M.J., Redon C., Pilch D.R., Olaru A., Eckhaus M., Camerini-Otero R.D., Tessarollo L., Livak F., Manova K., Bonner W.M., Nussenzweig M.C., Nussenzweig A Genomic instability in mice lacking histone H2AX. Science. 296:2002;922-927.
57. Bassing C.H., Chua K.F., Sekiguchi J., Suh H., Whitlow S.R., Fleming J.C., Monroe B.C., Ciccone D.N., Yan C., Vlasakova K., Livingston D.M., Ferguson D.O., Scully R., Alt F.W. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8173-8178.
58. Morrison C., Sonoda E., Takao N., Shinohara A., Yamamoto K.i., Takeda S. The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J. 19:2000;463-471.
59. Xu Y., Ashley T., Brainerd E.E., Bronson R.T., Meyn M.S., Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10:1996;2411-2424.
60. Barlow C., Hirotsune S., Paylor R., Liyanage M., Eckhaus M., Collins F., Shiloh Y., Crawley J.N., Ried T., Tagle D., Wynshaw-Boris A. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 86:1996;159-171.
61. Barlow C., Eckhaus M.A., Schaffer A.A., Wynshaw-Boris A. Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice. Nat. Genet. 21:1999;359-360.
62. Worgul B.V., Smilenov L., Brenner D.J., Junk A., Zhou W., Hall E.J. Atm heterozygous mice are more sensitive to radiation-induced cataracts than are their wild-type counterparts. Proc. Natl. Acad. Sci. U.S.A. 99:2002;9836-9839.
63. -/- mice. Mol. Cell. Biol. 18:1998;4385-4390.
64. Westphal C.H., Schmaltz C., Rowan S., Elson A., Fisher D.E., Leder P. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res. 57:1997;1664-1667.
65. Wang Y.A., Elson A., Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 94:1997;14590-14595.
66. Li N., Banin S., Ouyang H., Li G.C., Courtois G., Shiloh Y., Karin M., Rotman G. ATM Is Required for Ikappa B Kinase (IKK) Activation in Response to DNA Double Strand Breaks. J. Biol. Chem. 276:2001;8898-8903.
67. Yuan Z.M., Huang Y., Ishiko T., Nakada S., Utsugisawa T., Kharbanda S., Wang R., Sung P., Shinohara A., Weichselbaum R., Kufe D. Regulation of Rad51 function by c-Ab1 in response to DNA damage. J. Biol. Chem. 272:1998;3799-3802.
68. Chen G., Yuan S.S., Liu W., Xu Y., Trujillo K., Song B., Cong F., Goff S.P., Wu Y., Arlinghaus R., Baltimore D., Gasser P.J., Park M.S., Sung P., Lee E.Y. Radiation-induced assembly of Rad5l and Rad52 recombination complex requires ATM and c-Ab1. J. Biol. Chem. 274:1999;12748-12752.
69. Takao N., Mori R., Kato H., Shinohara A., Yamamoto K.i. c-Ab1 tyrosine kinase is not essential for ataxia telangiectasia mutated functions in chromosomal maintenance. J. Biol. Chem. 275:2000;725-728.
70. Khanna K.K. Cancer risk and the ATM gene: a continuing debate. J. Natl. Cancer Inst. 92:2000;795-802.
71. Swift M. Public health burden of cancer in ataxia-telangiectasia heterozygotes. J. Natl. Cancer. Inst. 93:2001;84-85.
72. Chenevix-Trench G., Spurdle A.B., Gatei M., Kelly H., Marsh A., Chen X., Donn K., Cummings M., Nyholt D., Jenkins M.A., Scott C., Pupo G.M., Dork T., Bendix R., Kirk J., Tucker K., McCredie M.R., Hopper J.L., Sambrook J., Mann G.J., Khanna K.K. Dominant negative ATM mutations in breast cancer families. J. Natl. Cancer Inst. 94:2002;205-215.
73. Smith G.C., Cary R.B., Lakin N.D., Hann B.C., Teo S.H., Chen D.J., Jackson S.P. Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM. Proc. Natl. Acad. Sci. U.S.A. 96:1999;11134-11139.
74. Neubauer S., Arutyunyan R., Stumm M., Dork T., Bendix R., Bremer M., Varon R., Sauer R., Gebhart E. Radiosensitivity of ataxia telangiectasia and Nijmegen breakage syndrome homozygotes and heterozygotes as determined by three-color FISH chromosome painting. Radiat. Res. 157:2002;312-321.
75. Weemaes C.M., Hustinx T.W., Scheres J.M., van Munster P.J., Bakkeren J.A., Taalman R.D. A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta Paediatr. Scand. 70:1981;557-564.
76. Carney J.P., Maser R.S., Olivares H., Davis E.M., Le Beau M., Yates J.R. III, Hays L., Morgan W.F., Petrini J.H. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell. 93:1998;477-486.
77. Varon R., Vissinga C., Platzer M., Cerosaletti K.M., Chrzanowska K.H., Saar K., Beckmann G., Seemanová E., Cooper P.R., Nowak N.J., Stumm M., Weemaes C.M.R., Gatti R.A., Wilson R.K., Digweek M., Rosenthal A., Sperling K., Concannon P., Reis A. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen Breakage syndrome. Cell. 93:1998;467-476.
78. Matsuura S., Tauchi H., Nakamura A., Kondo N., Sakamoto S., Endo S., Smeets D., Solder B., Belohradsky B.H., Der Kaloustian V.M., Oshimura M., Isomura M., Nakamura Y., Komatsu K. Positional cloning of the gene for Nijmegen breakage syndrome. Nat. Genet. 19:1998;179-181.
79. Shiloh Y. Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu. Rev. Genet. 31:1997;635-662.
80. Digweed M., Reis A., Sperling K. Nijmegen breakage syndrome: consequences of defective DNA double strand break repair. Bioessays. 21:1999;649-656.
81. Girard P.M., Foray N., Stumm M., Waugh A., Riballo E., Maser R.S., Phillips W.P., Petrini J., Arlett C.F., Jeggo P.A. Radiosensitivity in Nijmegen breakage syndrome cells is attributable to a repair defect and not cell cycle checkpoint defects. Cancer Res. 60:2000;4881-4888.
82. Kang J., Bronson R.T., Xu Y. Targeted disruption of NBS1 reveals its roles in mouse development and DNA repair. EMBO J. 21:2002;1447-1455.
83. Sullivan K.E., Veksler E., Lederman H., Lees-Miller S.P. Cell cycle checkpoints and DNA repair in Nijmegen breakage syndrome. Clin. Immunol. Immunopathol. 82:1997;43-48.
84. Jongmans W., Vuillaume M., Chrzanowska K., Smeets D., Sperling K., Hall J. Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionizing radiation. Mol. Cell. Biol. 17:1997;5016-5022.
85. Yamazaki V., Wegner R.D., Kirchgessner C.U. Characterization of cell cycle checkpoint responses after ionizing radiation in Nijmegen breakage syndrome cells. Cancer Res. 58:1998;2316-2322.
86. Matsuura K., Balmukhanov T., Tauchi H., Weemaes C., Smeets D., Chrzanowska K., Endou S., Matsuura S., Komatsu K. Radiation induction of p53 in cells from Nijmegen breakage syndrome is defective but not similar to ataxia-telangiectasia. Biochem. Biophys. Res. Commun. 242:1998;602-607.
87. Antoccia A., Stumm M., Saar K., Ricordy R., Maraschio P., Tanzarella C. Impaired p53-mediated DNA damage response, cell-cycle disturbance and chromosome aberrations in Nijmegen breakage syndrome lymphoblastoid cell lines. Int. J. Radiat. Biol. 75:1999;583-591.
88. Falck J., Petrini J.H., Williams B.R., Lukas J., Bartek J. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat. Genet. 30:2002;290-294.
89. Buscemi G., Savio C., Zannini L., Micciche F., Masnada D., Nakanishi M., Tauchi H., Komatsu K., Mizutani S., Khanna K., Chen P., Concannon P., Chessa L., Delia D. Chk2 activation dependence on NBS1 after DNA damage. Mol. Cell. Biol. 21:2001;5214-5222.
90. Ito A., Tauchi H., Kobayashi J., Morishima K., Nakamura A., Hirokawa Y., Matsuura S., Ito K., Komatsu K. Expression of full-length NBS1 protein restores normal radiation responses in cells from Nijmegen breakage syndrome patients. Biochem. Biophys. Res. Commun. 265:1999;716-721.
91. van Engelen B.G., Hiel J.A., Gabreels F.J., van den Heuvel L.P., van Gent D.C., Weemaes C.M. Decreased immunoglobulin class switching in Nijmegen breakage syndrome due to the DNA repair defect. Hum. Immunol. 62:2001;1324-1327.
92. Ranganathan V., Heine W.F., Ciccone D.N., Rudolph K.L., Wu X., Chang S., Hai H., Ahearn I.M., Livingston D.M., Resnick I., Rosen F., Seemanova E., Jarolim P., DePinho R.A., Weaver D.T. Rescue of a telomere length defect of Nijmegen breakage syndrome cells requires NBS and telomerase catalytic subunit. Curr. Biol. 11:2001;926-962.
93. Dolganov G.M., Maser R.S., Novikov A., Tosto L., Chong S., Bressan D.A., Petrini J.H. Human Rad50 is physically associated with human Mre11: identification of a conserved multiprotein complex implicated in recombinational DNA repair. Mol. Cell. Biol. 16:1996;4832-4841.
94. Nelms B.E., Maser R.S., MacKay J.F., Lagally M.G., Petrini J.H.J. In situ visualization of DNA double-strand break repair in human fibroblasts. Science. 280:1998;590-592.
95. Maser R.S., Monsen K.J., Nelms B.E., Petrini J.H.J. hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks. Mol. Cell. Biol. 17:1997;6097-6104.
96. Desai-Mehta A., Cerosaletti K.M., Concannon P. Distinct functional domains of nibrin mediate Mre11 binding, focus formation, and nuclear localization. Mol. Cell. Biol. 21:2001;2184-2191.
97. Mirzoeva O.K., Petrini J.H. DNA damage-dependent nuclear dynamics of the mre11 complex. Mol. Cell. Biol. 21:2001;281-288.
98. Lim D.S., Kim S.T., Xu B., Maser R.S., Lin J., Petrini J.H., Kastan M.B. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature. 404:2000;613-617.
99. Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G., Livingston D.M., Weaver D.T. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature. 405:2000;477-482.
100. Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S., Lavin M.F., Gatti R.A., Concannon P., Khanna K. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat. Genet. 25:2000;115-119.
101. Zhao S., Weng Y.C., Yuan S.S., Lin Y.T., Hsu H.C., Lin S.C., Gerbino E., Song M.H., Zdzienicka M.Z., Gatti R.A., Shay J.W., Ziv Y., Shiloh Y., Lee E.Y. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature. 405:2000;473-477.
102. Maser R.S., Zinkel R., Petrini J.H. An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. Nat. Genet. 27:2001;417-421.
103. Williams B.R., Mirzoeva O.K., Morgan W.F., Lin J., Dunnick W., Petrini J.H. A murine model of Nijmegen breakage syndrome. Curr. Biol. 12:2002;648-653.
104. Zhu J., Petersen S., Tessarollo L., Nussenzweig A. Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice. Curr. Biol. 11:2001;105-109.
105. Stumm M., von Ruskowsky A., Siebert R., Harder S., Varon R., Wieacker P., Schlegelberger B. No evidence for deletions of the NBS1 gene in lymphomas. Cancer Genet. Cytogenet. 126:2001;60-62.
106. Stewart G.S., Maser R.S., Stankovic T., Bressan D.A., Kaplan M.I., Jaspers N.G., Raams A., Byrd P.J., Petrini J.H., Taylor A.M. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell. 99:1999;577-587.
107. Petrini J.H. The mammalian Mre11-Rad50-nbs1 protein complex: integration of functions in the cellular DNA-damage response. Am. J. Hum. Genet. 64:1999;1264-1269.
108. Petrini J.H. The Mre11 complex and ATM: collaborating to navigate S phase. Curr. Opin. Cell Biol. 12:2000;293-296.
109. Xiao Y., Weaver D.T. Conditional gene targeted deletion by Cre recombinase demonstrates the requirement for the double-strand break repair Mre11 protein in murine embryonic stem cells. Nucl. Acids Res. 25:1997;2985-2991.
110. Yamaguchi-Iwai Y., Sonoda E., Sasaki M.S., Morrison C., Haraguchi T., Hiraoka Y., Yamashita Y.M., Yagi T., Takata M., Price C., Kakazu N., Takeda S. Mre11 is essential for the maintenance of chromosomal DNA in vertebrate cells. EMBO J. 18:1999;6619-6629.
111. Luo G., Yao M.S., Bender C.F., Mills M., Bladi A.R., Bradley A., Petrini J.H. Disruption of mRad50 causes embryonic stem cell lethality, abnormal embryonic development, and sensitivity to ionizing radiation. Proc. Natl. Acad. Sci. U.S.A. 96:1999;7376-7381.
112. Trujillo K.M., Yuan S.S., Lee E.Y., Sung P. Nuclease activities in a complex of human recombination and DNA repair factors Rad50, Mre11, and p95. J. Biol. Chem. 273:1998;21447-21450.
113. Paull T.T., Gellert M. The 3′ to 5′ exonuclease activity of Mre11 facilitates repair of DNA double-strand breaks. Mol. Cell. 1:1998;969-979.
114. Paull T.T., Gellert M. Nbs1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex. Genes Dev. 13:1999;1276-1288.
115. Huang J., Dynan W.S. Reconstitution of the mammalian DNA double-strand break end-joining reaction reveals a requirement for an Mre11/Rad50/NBS1-containing fraction. Nucl. Acids Res. 30:2002;667-674.
116. German J. Bloom syndrome: a Mendelian prototype of somatic mutational disease. Medicine. 72:1993;393-406.
117. van Brabant A.J., Stan R., Ellis N.A. DNA helicases, genomic instability, and human genetic disease. Annu. Rev. Genomics Hum. Genet. 1:2000;409-459.
118. Hickson I.D., Davies S.L., Li J.L., Levitt N.C., Mohaghegh P., North P.S., Wu L. Role of the Bloom's syndrome helicase in maintenance of genome stability. Biochem. Soc. Trans. 29:2001;201-204.
119. Chaganti R.S.K., Schonberg S., German J. A manyfold increase in sister chromatid exchanges in Bloom's syndrome lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 71:1974;4508-4512.
120. Warren S.T., Schultz R.A., Chang C.C., Wade M.H., Trosko J.E. Elevated spontaneous mutation rate in Bloom syndrome fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 78:1981;3133-3137.
121. Langlois R.G., Bigbee W.L., Jensen R.H., German J. Evidence for increased in vivo mutation and somatic recombination in Bloom's syndrome. Proc. Natl. Acad. Sci. U.S.A. 86:1989;670-674.
122. Franchitto A., Pichierri P. Bloom's syndrome protein is required for correct relocalization of RAD50/MRE11/NBS1 complex after replication fork arrest. J. Cell. Biol. 157:2002;19-30.
123. Beamish H., Kedar P., Kaneko H., Chen P., Fukao T., Peng C., Beresten S., Gueven N., Purdie D., Lees-Miller S., Ellis N., Kondo N., Lavin M.F. Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia mutated protein, ATM. J. Biol. Chem. 277:2002;30515-30523.
124. Ellis N.A., Groden J., Ye T.Z., Straughen J., Lennon D.J., Ciocci S., Proytcheva M., German J. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell. 83:1995;655-666.
125. Karow J.K., Wu L., Hickson I.D. RecQ family helicases: roles in cancer and aging. Curr. Opin. Genet. Dev. 10:2000;32-38.
126. Chester N., Kuo F., Kozak C., O'Hara C.D., Leder P. Stage-specific apoptosis, developmental delay, and embryonic lethality in mice homozygous for a targeted disruption in the murine Bloom's syndrome gene. Genes Dev. 12:1998;3382-3393.
127. Wu L., Davies S.L., Levitt N.C., Hickson I.D. Potential role for the BLM helicase in recombinational repair via a conserved interaction with RAD51. J. Biol. Chem. 276:2001;19375-19381.
128. Bischof O., Kim S.H., Irving J., Beresten S., Ellis N.A., Campisi J. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J. Cell. Biol. 153:2001;367-380.
129. Ababou M., Dutertre S., Lecluse Y., Onclercq R., Chatton B., Amor-Gueret M. ATM-dependent phosphorylation and accumulation of endogenous BLM protein in response to ionizing radiation. Oncogene. 19:2000;5955-5963.
130. Langland G., Kordich J., Creaney J., Goss K.H., Lillard-Wetherell K., Bebenek K., Kunkel T.A., Groden J. The Bloom's syndrome protein (BLM) interacts with MLH1 but is not required for DNA mismatch repair. J. Biol. Chem. 276:2001;30031-30035.
131. Pedrazzi G., Perrera C., Blaser H., Kuster P., Marra G., Davies S.L., Ryu G.H., Freire R., Hickson I.D., Jiricny J., Stagliar I. Direct association of Bloom's syndrome gene product with the human mismatch repair protein MLH1. Nucl. Acids Res. 29:2001;4378-4386.
132. Mohaghegh P., Karow J.K., Brosh R.M. Jr., Bohr V.A., Hickson I.D. The Bloom's and Werner's syndrome proteins are DNA structure-specific helicases. Nucl. Acids Res. 29:2001;2843-2849.
133. Wang W., Seki M., Narita Y., Sonoda E., Takeda S., Yamada K., Masuko T., Katada T., Enomoto T. Possible association of BLM in decreasing DNA double strand breaks during DNA replication. EMBO J. 19:2000;3428-3435.
134. Johnson R.D., Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J. 19:2000;3398-3407.
135. Wang X.W., Tseng A., Ellis N.A., Spillare E.A., Linke S.P., Robles A.I., Seker H., Yang Q., Hu P., Beresten S., Bemmels N.A., Garfield S., Harris C.C. Functional interaction of p53 and BLM DNA helicase in apoptosis. J. Biol. Chem. 276:2001;32948-32955.
136. Garkavtsev I.V., Kley N., Grigorian I.A., Gudkov A.V. The Bloom syndrome protein interacts and cooperates with p53 in regulation of transcription and cell growth control. Oncogene. 20:2001;8276-8280.
137. Bischof O., Galande S., Farzaneh F., Kohwi-Shigematsu T., Campisi J. Selective cleavage of BLM, the bloom syndrome protein, during apoptotic cell death. J. Biol. Chem. 276:2001;12068-12075.
138. Freire R., d'Adda Di Fagagna F., Wu L., Pedrazzi G., Stagljar I., Hickson I.D., Jackson S.P. Cleavage of the Bloom's syndrome gene product during apoptosis by caspase-3 results in an impaired interaction with topoisomerase IIIalpha. Nucl. Acids Res. 29:2001;3172-3180.
139. Shen J., Loeb L.A. Unwinding the molecular basis of the Werner syndrome. Mech. Ageing Dev. 122:2001;921-944.
140. Darlington G.J., Dutkowski R., Brown W.T. Sister chromatid exchange frequencies in Progeria and Werner syndrome patients. Am. J. Hum. Genet. 33:1981;762-766.
141. Imamura O., Fujita K., Itoh C., Takeda S., Furuichi Y., Matsumoto T. Werner and Bloom helicases are involved in DNA repair in a complementary fashion. Oncogene. 21:2002;954-963.
142. Lebel M., Leder P. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13097-13102.
143. Pichierri P., Franchitto A., Mosesso P., Palitti F. Werner's syndrome cell lines are hypersensitive to camptothecin-induced chromosomal damage. Mutat. Res. 456:2000;45-57.
144. Poot M., Yom J.S., Whang S.H., Kato J.T., Gollahon K.A., Rabinovitch P.S. Werner syndrome cells are sensitive to DNA cross-linking drugs. FASEB J. 15:2001;1224-1226.
145. Yannone S.M., Roy S., Chan D.W., Murphy M.B., Huang S., Campisi J., Chen D.J. Werner syndrome protein is regulated and phosphorylated by DNA-dependent protein kinase. J. Biol. Chem. 276:2001;38242-38248.
146. Pichierri P., Franchitto A., Mosesso P., Palitti F. Werner's syndrome protein is required for correct recovery after replication arrest and DNA damage induced in S-phase of cell cycle. Mol. Biol. Cell. 12:2001;2412-2421.
147. Poot M., Gollahon K.A., Rabinovitch P.S. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum. Genet. 104:1999;10-14.
148. Yu C.E., Oshima J., Fu Y.H., Wijsman E.M., Hisama F., Alisch R., Matthews S., Nakura J., Miki T., Ouais S., Martin G.M., Mulligan J., Schellenberg G.D. Positional cloning of the Werner's syndrome gene. Science. 272:1996;258-262.
149. Huang S., Li B., Gray M.D., Oshima J., Mian I.S., Campisi J. The premature ageing syndrome protein, WRN, is a 3′ → 5′ exonuclease. Nat. Genet. 20:1998;114-116.
150. Huang S., Beresten S., Li B., Oshima J., Ellis N.A., Campisi J. Characterization of the human and mouse WRN 3′ → 5′ exonuclease. Nucl. Acids Res. 28:2000;2396-2405.
151. Moser M.J., Kamath-Loeb A.S., Jacob J.E., Bennett S.E., Oshima J., Monnat R.J. Jr. WRN helicase expression in Werner syndrome cell lines. Nucl. Acids Res. 28:2000;648-654.
152. Lombard D.B., Beard C., Johnson B., Marciniak R.A., Dausman J., Bronson R., Buhlmann J.E., Lipman R., Curry R., Sharpe A., Jaenisch R., Guarente L. Mutations in the WRN gene in mice accelerate mortality in a p53-null background. Mol. Cell. Biol. 20:2000;3286-3291.
153. Lebel M., Cardiff R.D., Leder P. Tumorigenic effect of nonfunctional p53 or p21 in mice mutant in the Werner syndrome helicase. Cancer Res. 61:2001;1816-1819.
154. Brosh R.M. Jr., Bohr V.A. Roles of the Werner syndrome protein in pathways required for maintenance of genome stability. Exp. Gerontol. 37:2002;491-506.
155. Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Lees Miller S.P., Cheng W.H., Snowdon C.M., Ramsden D.A., Bohr V.A. Werner protein is a target of DNA-PK in vivo and in vitro, and its catalytic activities are regulated by phosphorylation. J. Biol. Chem. 277:2002;18291-18302.
156. Brosh R.M. Jr., von Kobbe C., Sommers J.A., Karmakar P., Opresko P.L., Piotrowski J., Dianova I., Dianov G.L., Bohr V.A. Werner syndrome protein interacts with human flap endonuclease 1 and stimulates its cleavage activity. EMBO J. 20:2001;5791-5801.
157. Oshima J., Huang S., Pae C., Campisi J., Schiestl R.H. Lack of WRN results in extensive deletion at nonhomologous joining ends. Cancer Res. 62:2002;547-551.
158. Prince P.R., Emond M.J., Monnat R.J. Jr. Loss of Werner syndrome protein function promotes aberrant mitotic recombination. Genes Dev. 15:2001;933-938.
159. Saintigny Y., Makienko K., Swanson C., Edmond M.J., Monnat R.J. Jr. Homologous recombination resolution defect in Werner syndrome. Mol. Cell. Biol. 22:2002;6971-6978.
160. Constantinou A., Tarsounas M., Karow J.K., Brosh R.M., Bohr V.A., Hickson I.D., West S.C. Werner's syndrome protein (WRN) migrates Holliday junctions and co-localizes with RPA upon replication arrest. EMBO Rep. 1:2000;80-84.
161. Sakamoto S., Nishikawa K., Heo S.J., Goto M., Furuichi Y., Shimamoto A. Werner helicase relocates into nuclear foci in response to DNA damaging
162. Lindor N.M., Furuichi Y., Kitao S., Shimamoto A., Arndt C., Jalal S. Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome. Am. J. Med. Genet. 90:2000;223-228.
163. Kitao S., Lindor N.M., Shiratori M., Furuichi Y., Shimamoto A. Rothmund-Thomson syndrome responsible gene. RECQ4: genomic structure and products. Genomics. 61:1999;268-276.
164. Kitao S., Shimamoto A., Goto M., Miller R.W., Smithson W.A., Lindor N.M., Furuichi Y. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat. Genet. 22:1999;82-84.
165. Buchwald M., Moustacchi E. Is Fanconi anemia caused by a defect in the processing of DNA damage? Mutat. Res. 408:1998;75-90.
166. Grompe M., D'Andrea A. Fanconi anemia and DNA repair. Hum. Mol. Genet. 10:2001;2253-2259.
167. Joenje H., Patel K.J. The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet. 2:2001;446-457.
168. Yamashita T., Nakahata T. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes. Int. J. Hematol. 74:2001;33-41.
169. Auerbach A.D., Adler B., Chaganti R.S. Prenatal and postnatal diagnosis and carrier detection of Fanconi anemia by a cytogenetic method. Pediatrics. 67:1981;128-135.
170. Cheng N.C., van De Vrugt H.J., van Der Valk M.A., Oostra A.B., Krimpenfort P., de Vries Y., Joenje H., Berns A., Arwert F. Mice with a targeted disruption of the fanconi anemia homolog Fanca. Hum. Mol. Genet. 9:2000;1805-1881.
171. Noll M., Battaile K.P., Bateman R., Lax T.P., Rathbun K., Reifsteck C., Bagby G., Finegold M., Olson S., Grompe M. Fanconi anemia group A and C double-mutant mice. Functional evidence for a multi-protein Fanconi anemia complex. Exp. Hematol. 30:2002;679-688.
172. Whitney M.A., Royle G., Low M.J., Kelly M.A., Axthelm M.K., Reifsteck C., Olson S., Braun R.E., Heinrich M.C., Rathbun R.K., Bagby G.C., Grompe M. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood. 88:1996;49-58.
173. Chen M., Tomkins D.J., Auerbach W., McKerlie C., Youssoufian H., Liu L., Gan O., Carreau M., Auerbach A., Groves T., Guidos C.J., Freedman M.H., Cross J., Percy D.H., Dick J.E., Joyner A.L., Buchwald M. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat. Genet. 12:1996;448-451.
174. Yang Y., Kuang Y., De Oca R.M., Hays T., Moreau L., Lu N., Seed B., D'Andrea A.D. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood. 98:2001;3435-3440.
175. Koomen M., Cheng N.C., van de Vrugt H.J., Godthelp B.C., van der Valk M.A., Oostra A.B., Zdzienicka M.Z., Joenje H., Arwert F. Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice. Hum. Mol. Genet. 11:2002;273-281.
176. Kupfer G.M., Naf D., Suliman A., Pulsipher M., D'Andrea A.D. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nat. Genet. 17:1997;487-490.
177. Garcia-Higuera I., Kuang Y., Naf D., Wasik J., D'Andrea A.D. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol. Cell. Biol. 19:1999;4866-4873.
178. de Winter J.P., van Der Weel L., de Groot J., Stone S., Waisfisz Q., Arwert F., Scheper R.J., Kruyt F.A., Hoatlin M.E., Joenje H. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum. Mol. Genet. 9:2000;2665-2674.
179. Pace P., Johnson M., Tan W.M., Mosedale G., Sng C., Hoatlin M., De Winter J., Joenje H., Gergely F., Patel K.J. FANCE: the link between Fanconi anaemia complex assembly and activity. EMBO J. 21:2002;3414-3423.
180. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., Grompe M., D'Andrea A.D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell. 7:2001;249-262.
181. Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., Kim S.T., Lane W.S., Kastan M.B., D'Andrea A.D. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell. 109:2002;459-472.
182. Stewart G., Elledge S.J. The two faces of BRCA2, a FANCtastic discovery. Mol. Cell. 10:2002;2-4.
183. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H., Fox E.A., D'Andrea A.D. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 297:2002;606-609.
184. Wilson J.B., Johnson M.A., Stuckert A.P., Trueman K.L., May S., Bryant P.E., Meyn R.E., D'Andrea A.D., Jones N.J. The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquinated form of the FAND2 protein, is hypersensitive to a range of DNA damaging agents, and exhibits a normal level of spontaneous sister chromatid exchange. Carcinogenesis. 22:2001;1939-1946.
185. Nathanson K.L., Wooster R., Weber B.L., Nathanson K.N. Breast cancer genetics: what we know and what we need. Nat. Med. 7:2001;552-556.
186. Gowen L.C., Avrutskaya A.V., Latour A.M., Koller B.H., Leadon S.A. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science. 281:1998;1009-1012.
187. Le Page F., Randrianarison V., Marot D., Cabannes J., Perricaudet M., Feunteun J., Sarasin A. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res. 60:2000;5548-5552.
188. Chen J., Silver D.P., Walpita D., Cantor S.B., Gazdar A.F., Tomlinson G., Couch F.J., Weber B.L., Ashley T., Livingston D.M., Scully R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell. 2:1998;317-328.
189. Zheng L., Li S., Boyer T.G., Lee W.H. Lessons learned from BRCA1 and BRCA2. Oncogene. 19:2000;6159-6175.
190. Welcsh P.L., Owens K.N., King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet. 16:2000;69-74.
191. Scully R., Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 408:2000;429-432.
192. Welcsh P.L., King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10:2001;705-713.
193. Kerr P., Ashworth A. New complexities for BRCA1 and BRCA2. Curr. Biol. 11:2001;R668-R676.
194. Liu Y., West S.C. Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res. 4:2002;9-13.
195. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 108:2002;171-182.
196. Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275:2000;23899-23903.
197. Yuan S.S., Lee S.Y., Chen G., Song M., Tomlinson G.E., Lee E.Y. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 59:1999;3547-3551.
198. Moynahan M.E., Chiu J.W., Koller B.H., Jasin M. Brca1 controls homology-directed DNA repair. Mol. Cell. 4:1999;511-518.
199. Moynahan M.E., Cui T.Y., Jasin M. Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61:2001;4842-4850.
200. Paull T.T., Cortez D., Bowers B., Elledge S.J., Gellert M. Direct DNA binding by Brca1. Proc. Natl. Acad. Sci. U.S.A. 98:2001;6086-6091.
201. Zhong Q., Chen C.F., Chen P.L., Lee W.H. BRCA1 facilitates micro-homology mediated end-joining of DNA double-strand breaks. J. Biol. Chem. 277:2002;28641-28647.
202. Zhong Q., Boyer T.G., Chen P.L., Lee W.H. Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res. 62:2002;3966-3970.
203. Cortez D., Wang Y., Qin J., Elledge S.J. Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks. Science. 286:1999;1162-1166.
204. Gatei M., Zhou B.B., Hobson K., Scott S., Young D., Khanna K.K. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J. Biol. Chem. 276:2001;17276-17280.
205. Lee J.S., Collins KM., Brown A.L., Lee C.H., Chung J.H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature. 404:2000;201-204.
206. Tibbetts R.S., Cortez D., Brumbaugh K.M., Scully R., Livingston D., Elledge S.J., Abraham R.T. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev. 14:2000;2989-3002.
207. Li S., Ting N.S., Zheng L., Chen P.L., Ziv Y., Shiloh Y., Lee E.Y., Lee W.H. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature. 406:2000;210-215.
208. Xu X., Weaver Z., Linke S.P., Li C., Gotay J., Wang X.W., Harris C.C., Ried T., Deng C.X. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell. 3:1999;389-395.
209. Xu B., Kim S.T., Kastan M.B. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol. Cell. Biol. 21:2001;3445-3450.
210. Yarden R.I., Pardo-Reoyo S., Sgagias M., Cowan K.H., Brody L.C. BRCA1 regulates the G2/M checkpoint by activating Chkl kinase upon DNA damage. Nat. Genet. 30:2002;285-289.
211. Deming P.B., Cistulli C.A., Zhao H., Graves P.R., Piwnica-Worms H., Paules R.S., Downes C.S., Kaufmann W.K. The human decatenation checkpoint. Proc. Natl. Acad. Sci. U.S.A. 98:2001;12044-12049.
212. Hsu L.C., White R.L. BRCA1 is associated with the centrosome during mitosis. Proc. Natl. Acad. Sci. U.S.A. 95:1998;12983-12988.
213. Hsu L.C., Doan T.P., White R.L. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res. 61:2001;7713-7718.
214. Zhong Q., Chen C.F., Li S., Chen Y., Wang C.C., Xiao J., Chen P.L., Sharp Z.D., Lee W.H. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 285:1999;747-750.
215. Schlegel B.P., Green V.J., Ladias J.A., Parvin J.D. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and Hrpb10alpha in activated transcription. Proc. Natl. Acad. Sci. U.S.A. 97:2000;3148-3153.
216. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14:2000;927-939.
217. Chiba N., Parvin J.D. Redistribution of BRCA1 among four different protein complexes following replication blockage. J. Biol. Chem. 276:2001;38549-38554.
218. Chiba N., Parvin J.D. The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. Cancer Res. 62:2002;4222-4228.
219. Li H., Lee T.H., Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 277:2002;20965-20973.
220. Wu X., Petrini J.H., Heine W.F., Weaver D.T., Livingston D.M., Chen J. Independence of R/M/N focus formation and the presence of intact BRCA1. Science. 289:2000;11.
221. Brzovic P.S., Rajagopal P., Hoyt D.W., King M.C., Klevit R.E. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat. Struct. Biol. 8:2001;833-837.
222. Morris J.R., Keep N.H., Solomon E. Identification of residues required for the interaction of BARD1 with BRCA1. J. Biol. Chem. 277:2002;9382-9386.
223. Hashizume R., Fukuda M., Maeda I., Nishikawa H., Oyake D., Yabuki Y., Ogata H., Ohta T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276:2001;14537-14540.
224. Chen A., Klciman F.E., Manley J.L., Ouchi T., Pan Z.Q. Autoubiquitination of the BRCA1*BARD1 RING ubiquitin ligase. J. Biol. Chem. 277:2002;22085-22092.
225. Brzovic P.S., Meza J., King M.C., Klevit R.E. The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain. J. Biol. Chem. 273:1998;7795-7799.
226. Brzovic P.S., Meza J.E., King M.C., Klevit R.E. BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J. Biol. Chem. 276:2001;41399-41406.
227. Ruffner H., Joazeiro C.A., Hemmati D., Hunter T., Verma I.M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5134-5139.
228. Kleiman F.E., Manley J.L. The BARD1-CstF-50 interaction links mRNA 3′ end formation to DNA damage and tumor suppression. Cell. 104:2001;743-753.
229. Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A., Ishov A.M., Tommerup N., Vissing H., Sekido Y., Minna J., Borodovsky A., Schultz D.C., Wilkinson K.D., Maul G.G., Barlev N., Berger S.L., Prendergast G.C., Rauscher F.J. III BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 16:1998;1097-1112.
230. Anderson S.F., Schlegel B.P., Nakajima T., Wolpin E.S., Parvin J.D. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19:1998;254-256.
231. Scully R., Anderson S.F., Chao D.M., Wei W., Ye L., Young R.A., Livingston D.M., Parvin J.D. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5605-5610.
232. Bochar D.A., Wang L., Beniya H., Kinev A., Xue Y., Lane W.S., Wang W., Kashanchi F., Shiekhattar R. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell. 102:2000;257-265.
233. Chai Y.L., Cui J., Shao N., Shyam E., Reddy P., Rao V.N. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene. 18:1999;263-268.
234. MacLachlan T.K., Somasundaram K., Sgagias M., Shifman Y., Muschel R.J., Cowan K.H., El-Deiry W.S. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J. Biol. Chem. 275:2000;2777-2785.
235. MacLachlan T.K., Takimoto R., El-Deiry W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol. 22:2002;4280-4292.
236. Houvras Y., Benezra M., Zhang H., Manfredi J.J., Weber B.L., Licht J.D. BRCA1 physically and functionally interacts with ATF1. J. Biol. Chem. 275:2000;36230-36237.
237. Yu X., Wu L.C., Bowcock A.M., Aronheim A., Baer R. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J. Biol. Chem. 273:1998;25388-25392.
238. Li S., Chen P.L., Subramanian T., Chinnadurai G., Tomlinson G., Osborne C.K., Sharp Z.D., Lee W.H. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J. Biol. Chem. 274:1999;11334-11338.
239. Yu X., Baer R. Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. J. Biol. Chem. 275:2000;18541-18549.
240. Sum E.Y., Peng B., Yu X., Chen J., Byrne J., Lindeman G.J., Visvader J.E. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J. Biol. Chem. 277:2002;7849-7856.
241. Zheng L., Pan H., Li S., Flesken-Nikitin A., Chen P.L., Boyer T.G., Lee W.H. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol. Cell. 6:2000;757-768.
242. Callebaut I., Mornon J.P. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett. 400:1997;25-30.
243. Bork P., Hofmann K., Bucher P., Neuwald A.F., Altschul S.F., Koonin E.V. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 11:1997;68-76.
244. Huyton T., Bates P.A., Zhang X., Sternberg M.J., Freemont P.S. The BRCA1 C-terminal domain: structure and function. Mutat. Res. 460:2000;319-332.
245. Yarden RI., Brody L.C. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. U.S.A. 96:1999;4983-4988.
246. Cantor S.B., Bell D.W., Ganesan S., Kass E.M., Drapkin R., Grossman S., Wahrer D.C., Sgroi D.C., Lane W.S., Haber D.A., Livingston D.M. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 105:2001;149-160.
247. Pao G.M., Janknecht R., Ruffner H., Hunter T., Verma I.M. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1020-1025.
248. Gowen L.C., Johnson B.L., Latour A.M., Sulik K.K., Koller B.H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12:1996;191-194.
249. Liu C.Y., Flesken-Nikitin A., Li S., Zeng Y., Lee W.H. Inactivation of the mouse Brca1 gene leads to failure in the moiphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10:1996;1835-1843.
250. Hakem R., de la Pompa J.L., Sirard C., Mo R., Woo M., Hakem A., Wakeham A., Potter J., Reitmair A., Billia F., Firpo E., Hui C.C., Roberts J., Rossant J., Mak T.W. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell. 85:1996;1009-1023.
251. Ludwig T., Chapman D.L., Papaioannou V.E., Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11:1997;1226-1241.
252. Xu X., Qiao W., Linke S.P., Cao L., Li W.M., Furth P.A., Harris C.C., Deng C.X. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumoriginesis. Nat. Genet. 28:2001;266-271.
253. Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M., Bansal R., Hruban R.H., Kern S.E. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 62:2002;3789-3793.
254. Sharan S.K., Morimatsu M., Albrecht U., Lim D.S., Regel E., Dinh C., Sands A., Eichele G., Hasty P., Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 386:1997;804-810.
255. Wong A.K.C., Pero R., Ormonde P.A., Tavtigian S.V., Bartel P.L. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene Brca2. J. Biol. Chem. 272:1997;31941-31944.
256. Marmorstein L.Y., Ouchi T., Aaronson S.A. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13869-13874.
257. Chen P.L., Chen C.F., Chen Y., Xiao J., Sharp Z.D., Lee W.H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc. Natl. Acad. Sci. U.S.A. 95:1998;5287-5292.
258. Davies A.A., Masson J.Y., Mcllwraith M.J., Stasiak A.Z., Stasiak A., Venkitaraman A.R., West S.C. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol. Cell. 7:2001;273-282.
259. Chen J.J., Silver D., Cantor S., Livingston D.M., Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 59:1999;1752s-1756s.
260. Yu V.P., Koehler M., Steinlein C., Schmid M., Hanakahi L.A., van Gool A.J., West S.C., Venkitaraman A.R. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev. 14:2000;1400-1406.
261. Morimatsu M., Donoho G., Hasty P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. Cancer Res. 58:1998;3441-3447.
262. Xia F., Taghian D.G., DeFrank J.S., Zeng Z.C., Willers H., Iliakis G., Powell S.N. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8644-8649.
263. Kraakman-van der Zwet M., Overkamp W.J., van Lange R.E., Essers J., van Duijn-Goedhart A., Wiggers I., Swaminathan S., van Buul P.P., Errami A., Tan R.T., Jaspers N.G., Sharan S.K., Kanaar R., Zdzienicka M.Z. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell. Biol. 22:2002;669-679.
264. Bork P., Blomberg N., Nilges M. Internal repeats in the BRCA2 protein sequence. Nat. Genet. 13:1996;22-23.
265. Bignell G., Micklem G., Stratton M.R., Ashworth A., Wooster R. The BRC repeats are conserved in mammalian BRCA2 proteins. Hum. Mol. Genet. 6:1997;53-58.
266. Chen C.F., Chen P.L., Zhong Q., Sharp Z.D., Lee W.H. Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad5l complex and leads to radiation hypersensitivity and loss of G(2)IM checkpoint control. J. Biol. Chem. 274:1999;32931-32935.
267. Connor F., Bertwistle D., Mee P.J., Ross G.M., Swift S., Grigorieva E., Tybulewicz V.L., Ashworth A. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat. Genet. 17:1997;423-430.
268. Patel K.J., Yu V.P., Lee H., Corcoran A., Thistlethwaite F.C., Evans M.J., Colledge W.H., Friedman L.S., Ponder B.A., Venkitaraman A.R. Involvement of Brca2 in DNA repair. Mol. Cell. 1:1998;347-357.
269. McAllister K.A., Bennett L.M., Houle C.D., Ward T., Malphurs J., Collins N.K., Cachafeiro C., Haseman J., Goulding E.H., Bunch D., Eddy E.M., Davis B.J., Wiseman R.W. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 62:2002;990-994.
270. Warren M., Smith A., Partridge N., Masabanda J., Griffin D., Ashworth A. Structural analysis of the chicken BRCA2 gene facilitates identification of functional domains and disease causing mutations. Hum. Mol. Genet. 11:2002;841-851.
271. Wang S.C., Shao R., Pao A.Y., Zhang S., Hung M.C., Su L.K. Inhibition of cancer cell growth by BRCA2. Cancer Res. 62:2002;1311-1314.
272. Bertwistle D., Swift S., Marston N.J., Jackson L.E., Crossland S., Crompton M.R., Marshall C.J., Ashworth A. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res. 57:1997;5485-5488.
273. Rajan J.V., Wang M., Marquis S.T., Chodosh L.A. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 93:1996;13078-13083.
274. Blackshear P.E., Goldsworthy S.M., Foley J.F., McAllister K.A., Bennett L.M., Collins N.K., Bunch D.O., Brown P., Wiseman R.W., Davis B.J. Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice. Oncogene. 16:1998;61-68.
275. Wang S.C., Lin S.H., Su L.K., Hung M.C. Changes in BRCA2 expression during progression of the cell cycle. Biochem. Biophys. Res. Commun. 234:1997;247-251.
276. Vaughn J.P., Cirisano F.D., Huper G., Berchuck A., Futreal P.A., Marks J.R., Iglehart J.D. Cell cycle control of BRCA2. Cancer Res. 56:1996;4590-4594.
277. Tutt A., Gabriel A., Bertwistle D., Connor F., Paterson H., Peacock J., Ross G., Ashworth A. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr. Biol. 9:1999;1107-1110.
278. Lee H., Trainer A.H., Friedman L.S., Thistlethwaite F.C., Evans M.J., Ponder B.A., Venkitaraman A.R. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol. Cell. 4:1999;1-10.
279. Liu N., Lamerdin J.E., Tebbs R.S., Schild D., Tucker J.D., Shen M.R., Brookman K.W., Siciliano M.J., Walter C.A., Fan W., Narayana L.S., Zhou Z.Q., Adamson A.W., Sorensen K.J., Chen D.J., Jones N.J., Thompson L.H. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA crosslinks and other damages. Mol. Cell. 1:1998;783-793.
280. Cartwright R., Tambini C.E., Simpson P.J., Thacker J. The XRCC2 DNA repair gene from human and mouse encodes a novel member of the recA/RAD51 family. Nucl. Acids Res. 26:1998;3084-3089.
281. Pierce A.J., Johnson R.D., Thompson L.H., Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13:1999;2633-2638.
282. Johnson R.D., Liu N., Jasin M. Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature. 401:1999;397-399.
283. Griffin C.S., Simpson P.J., Wilson C.R., Thacker J. Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation. Nat. Cell. Biol. 2:2000;757-761.
284. Takata M., Sasaki M.S., Sonoda E., Fukushima T., Morrison C., Albala J.S., Swagemakers S.M., Kanaar R., Thompson L.H., Takeda S. The Rad51 paralog Rad51B promotes homologous recombinational repair. Mol. Cell. Biol. 20:2000;6476-6482.
285. Takata M., Sasaki M.S., Tachuri S., Fukushima T., Sonoda E., Schild D., Thompson L.H., Takeda S. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol. Cell. Biol. 21:2001;2858-2866.
286. Ban S., Shinohara T., Hirai Y., Moritaku Y., Cologne J.B., Macphee D.G. Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay. Mutat. Res. 474:2001;15-23.
287. Godthelp B.C., Artwert F., Joenje H., Zdzienicka M.Z. Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1. Oncogene. 21:2002;5002-5005.
288. Weaver Z., Montagna C., Xu X., Howard T., Gadina M., Brodie S.G., Deng C.X., Ried T. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene. 21:2002;5097-5107.
289. Moynahan M.E., Pierce A.J., Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell. 7:2001;263-672.
290. Tutt A., Bertwistle D., Valentine J., Gabriel A., Swift S., Ross G., Griffin C., Thacker J., Ashworth A. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20:2001;4704-4716.
291. Sonoda E., Sasaki M.S., Morrison C., Yamaguchi-Iwai Y., Takata M., Takeda S. Sister chromatid exchanges are mediated by homologous recombination in vertebrate cells. Mol. Cell. Biol. 19:1999;5166-5169.
292. Takata M., Tachiiri S., Fujimori A., Thompson L.H., Miki Y., Hiraoka M., Takeda S., Yamazoe M. Conserved domains in the chicken homologue of BRCA2. Oncogene. 21:2002;1130-1134.
293. Milner J., Ponder B., Hughes-Davies L., Seltmann M., Kouzarides T. Transcriptional activation functions in BRCA2. Nature. 386:1997;772-773.
294. Fuks F., Milner J., Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene. 17:1998;2531-2534.
295. Liu J., Yuan Y., Huan J., Shen Z. Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2. Oncogene. 20:2001;336-345.
296. Marmorstein L.Y., Kinev A.V., Chan G.K., Bochar D.A., Beniya H., Epstein J.A., Yen T.J., Shiekhattar R. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Cell. 104:2001;247-257.
297. Marston N.J., Richards W.J., Hughes D., Bertwistle D., Marshall C.J., Ashworth A. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol. Cell. Biol. 19:1999;4633-4642.
298. Stark J.M., Hu P., Pierce A.J., Moynahan M.E., Ellis N., Jasin M. ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair. J. Biol. Chem. 277:2002;20185-20194.
299. Benson F.E., Baumann P., West S.C. Synergistic actions of Rad5l and Rad52 in recombination and DNA repair. Nature. 391:1998;401-404.
300. Mcllwraith M.J., Van Dyck E., Masson J.Y., Stasiak A.Z., Stasiak A., West S.C. Reconstitution of the strand invasion step of double-strand break repair using human Rad5l Rad52 and RPA proteins. J. Mol. Biol. 304:2000;151-164.
301. Kagawa W., Kurumizaka H., Ikawa S., Yokoyama S., Shibata T. Homologous pairing promoted by the human Rad52 protein. J. Biol. Chem. 276:2001;35201-35208.
302. Fujimori A., Tachuri S., Sonoda E., Dhar P.K., Hiraoka M., Takeda S., Thompson L.H., Takata M. Rad52 partially substitutes for the Rad51 paralog XRCC3 in maintaining chromosomal integrity in vertebrate cells. EMBO J. 20:2001;5513-5520.
303. Tanaka K., Kagawa W., Kinebuchi T., Kurumizaka H., Miyagawa K. Human Rad54B is a double-stranded DNA-dependent ATPase and has biochemical properties different from its structural homolog in yeast, Tid1/Rdh54. Nucl. Acids Res. 30:2002;1346-1353.
304. Miyagawa K., Tsuruga T., Kinomura A., Usui K., Katsura M., Tashiro S., Mishima H., Tanaka K. A role for RAD54B in homologous recombination in human cells. EMBO J. 21:2002;175-180.
305. Tanaka K., Hiramoto T., Fukuda T., Miyagawa K. A novel human Rad54 homologue, Rad54B, associates with Rad51. J. Biol. Chem. 275:2000;26316-26321.
306. Hiramoto T., Nakanishi T., Sumiyoshi T., Fukuda T., Matsuura S., Tauchi H., Komatsu K., Shibasaki Y., Inui H., Watatani M., Yasutomi M., Sumii K., Kajiyama G., Kamada N., Miyagawa K., Kamiya K. Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. Oncogene. 18:1999;3422-3426.
307. Pierce A.J., Stark J.M., Araujo F.D., Moynahan M.E., Berwick M., Jasin M. Double-strand breaks and tumorigenesis. Trends Cell Biol. 11:2001;S52-S59.
308. Raderschall E., Stout K., Freier S., Suckow V., Schweiger S., Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 62:2002;219-225.
309. Maacke H., Jost K., Opitz S., Miska S., Yuan Y., Hasselbach L., Luttges J., Kalthoff H., Sturzbecher H.W. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 19:2000;2791-2795.
310. Yoshikawa K., Ogawa T., Baer R., Hemmi H., Honda K., Yamauchi A., Inamoto T., Ko K., Yazumi S., Motoda H., Kodama H., Noguchi S., Gazdar A.F., Yamaoka Y., Takahashi R. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int. J. Cancer. 88:2000;28-36.
311. Slupianek A., Schmutte C., Tombline G., Nieborowska-Skorska M., Hoser G., Nowicki M.O., Pierce A.J., Fishel R., Skorski T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell. 8:2001;795-806.
312. Kim P.M., Allen C., Wagener B.M., Shen Z., Nickoloff J.A. Overexpression of human RAD51 and RAD52 reduces double-strand break-induced homologous recombination in mammalian cells. Nucl. Acids Res. 29:2001;4352-4360.
313. Arnaudeau C., Rozier L., Cazaux C., Defais M., Jenssen D., Helleday T. RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucl. Acids Res. 29:2001;662-667.
314. Flygare J., Falt S., Ottervald J., Castro J., Dackland A.L., Hellgren D., Wennborg A. Effects of HsRad51 overexpression on cell proliferation, cell cycle progression, and apoptosis. Exp. Cell Res. 268:2001;61-69.
315. Yanez R.J., Porter A.C. Differential effects of Rad52p overexpression on gene targeting and extrachromosomal homologous recombination in a human cell line. Nucl. Acids Res. 30:2002;740-748.
316. Godthelp B.C., Wiegant W.W., Van Duijn-Goedhart A., Scharer O.D., Van Buul P.P., Kanaar R., Zdzienicka M.Z. Mammalian Rad51C contributes to DNA cross-link resistance. Nucl. Acids Res. 30:2002;2172-2182.
317. French C.A., Masson J.Y., Griffin C.S., O'Regan P., West S.C., Thacker J. Role of mammalian RAD51L2 (RAD51C) in recombination and genetic stability. J. Biol. Chem. 277:2002;19322-19330.
318. Sung P. Yeast Rad55 and Rad57 proteins form a heterodimer that functions with RPA to promote DNA strand exchange by Rad51 recombinase. Genes Dev. 11:1997;1111-1121.
319. Masson J.Y., Tarsounas M.C., Stasiak A.Z., Stasiak A., Shah R., Mcllwraitb M.J., Benson F.E., West S.C. Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes Dev. 15:2001;3296-3307.
320. Wiese C., Collins D.W., Albala J.S., Thompson L.H., Kronenberg A., Schild D. Interactions involving the Rad51 paralogs Rad51C and XRCC3 in human cells. Nucl. Acids Res. 30:2002;1001-1008.
321. Liu N., Schild D., Thelen M.P., Thompson L.H. Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells. Nucl. Acids Res. 30:2002;1009-1015.
322. Miller K.A., Yoshikawa D.M., McConnell I.R., Clark R., Schild D., Albala J.S. RAD51C interacts with RAD51B and is central to a larger protein complex in vivo exclusive of RAD51. J. Biol. Chem. 277:2002;8406-8411.
323. Schoenmakers E.F., Huysmans C., Van de Ven W.J. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res. 59:1999;19-23.
324. Takahashi T., Nagai N., Oda H., Ohama K., Kamada N., Miyagawa K. Evidence for RAD51L1/HMGIC fusion in the pathogenesis of uterine leiomyoma. Genes Chromosomes Cancer. 30:2001;196-201.
325. Amant F., Debiec-Rychter M., Schoenmakers E.F., Hagemeijer-Hausman A., Vergote I. Cumulative dosage effect of a RAD51L1/HMGA2 fusion and RAD51L1 loss in a case of pseudo-Meigs syndrome. Genes Chromosomes Cancer. 32:2001;324-329.
326. Winsey S.L., Haldar N.A., Marsh H.P., Bunce M., Marshall S.E., Harris A.L., Wojnarowska F., Welsh K.I. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res. 60:2000;5612-5616.
327. Matullo G., Guarrera S., Carturan S., Peluso M., Malaveille C., Davico L., Piazza A., Vineis P. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int. J. Cancer. 92:2001;562-567.
328. Kuschel B., Auranen A., McBride S., Novik K.L., Antoniou A., Lipscombe J.M., Day N.E., Easton D.F., Ponder B.A., Pharoah P.D., Dunning A. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum. Mol. Genet. 11:2002;1399-1407.
329. David-Beabes G.L., Lunn R.M., London S.J. No association between the XPD (Lys751Gln) polymorphism or the XRCC3 (Thr241 Met) polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 10:2001;911-912.
330. Butkiewicz D., Rusin M., Enewold L., Shields P.G., Chorazy M., Harris C.C. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis. 22:2001;593-597.
331. Araujo F.D., Pierce A.J., Stark J.M., Jasin M. Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene. 21:2002;4176-4180.
332. Rafii S., O'Regan P., Xinarianos G., Azmy I., Stephenson T., Reed M., Meuth M., Thacker J., Cox A. A potential role for the XRCC2 RI88H polymorphic site in DNA-damage repair and breast cancer. Hum. Mol. Genet. 11:2002;1433-1438.
333. Barlund M., Monni O., Kononen J., Cornelison R., Torhorst J., Sauter G., Kallioniemi A. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 60:2000;5340-5344.
334. Wu G.J., Sinclair C.S., Paape J., Ingle J.N., Roche P.C., James C.D., Couch F.J. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res. 60:2000;5371-5375.
335. Masutani C., Kusumoto R., Yamada A., Dohmae N., Yokoi M., Yuasa M., Araki M., Iwai S., Takio K., Hanaoka F. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature. 399:1999;700-704.
336. Johnson R.E., Kondratick C.M., Prakash S., Prakash L. hRAD30 mutations in the variant form of xeroderma pigmentosum. Science. 285:1999;263-265.
337. Cleaver J.E., Afzal V., Feeney L., McDowell M., Sadinski W., Volpe J.P., Busch D.B., Coleman D.M., Ziffer D.W., Yu Y., Nagasawa H., Little J.B. Increased ultraviolet sensitivity and chromosomal instability related to P53 function in the xeroderma pigmentosum variant. Cancer Res. 59:1999;1102-1108.
338. Limoli C.L., Giedzinski E., Morgan W.F., Cleaver J.E. Inaugural article: polymerase eta deficiency in the xeroderma pigmentosum variant uncovers an overlap between the S phase checkpoint and double-strand break repair. Proc. Natl. Acad. Sci. U.S.A. 97:2000;7939-7946.
339. Limoli C.L., Giedzinski E., Bonner W.M., Cleaver J.E. UV-induced replication arrest in the xeroderma pigmentosum variant leads to DNA double-strand breaks, gamma-H2AX formation, and Mrel1 relocalization. Proc. Natl. Acad. Sci. U.S.A. 99:2002;233-238.
340. Appella E., Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2001;2764-2772.
341. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta. 1602:2002;47-59.
342. Ward I.M., Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J. Biol. Chem. 276:2001;47759-47762.
343. Pinkel D., Thompson L.H., Gray J.W., Vanderlaan M. Measurement of sister chromatid exchanges at very low bromodeoxyuridine substitution levels using a monoclonal antibody in Chinese hamster ovary cells. Cancer Res. 45:1985;5795-5798.
344. Potapova O., Basu S., Mercola D., Holbrook N.J. Protective role for c-Jun in the cellular response to DNA damage. J. Biol. Chem. 276:2001;28546-28553.
345. Elledge S.J., Amon A. The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. Cancer Cell. 1:2002;129-132.
346. Yazdi P.T., Wang Y., Zhao S., Patel N., Lee E.Y., Qin J. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev. 16:2002;571-582.
347. Kim S.T., Xu B., Kastan M.B. Involvement of the cohesin protein, Smcl, in Atm-dependent and independent responses to DNA damage. Genes Dev. 16:2002;560-570.
348. Chen M.J., Lin Y.T., Lieberman H.B., Chen G., Lee E.Y. Atm-dependent phosphorylation of human rad9 is required for ionizing radiation-induced checkpoint activation. J. Biol. Chem. 276:2001;16580-16586.
349. Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J. Ataxia telangiectasia-mutated phosphorylates chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10389-10394.
350. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60:2000;5934-5936.
351. Melchionna R., Chen X.B., Blasina A., McGowan C.H. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat. Cell. Biol. 2:2000;762-765.
352. Lee C.H., Chung J.H. The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J. Biol. Chem. 276:2001;30537-30541.
353. Ward I.M., Wu X., Chen J. Threonine 68 of Chk2 Is phosphorylated at sites of DNA strand breaks. J. Biol. Chem. 276:2001;47755-47758.
354. Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 20:1998;398-400.
355. Saito S., Goodarzi A.A., Higashimoto Y., Noda Y., Lees-Miller S.P., Appella E., Anderson C.W. ATM mediates phosphorylation at multiple p53 sites, including Ser46, in response to ionizing radiation. J. Biol. Chem. 277:2002;12491-12494.
356. Maya R., Balass M., Kim S.T., Shkedy D., Leal J.F., Shifman O., Moas M., Buschmann T., Ronai Z., Shiloh Y., Kastan M.B., Katzir E., Oren M. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15:2001;1067-1077.
357. Gatei M., Scott S.P., Filippovitch I., Soronika N., Lavin M.F., Weber B., Khanna K.K. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res. 60:2000;3299-3304.
358. Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., Kufe D., Lavin M.F. Interaction between ATM protein and c-Ab1 in response to DNA damage. Nature. 387:1997;520-523.
359. Baskaran R., Wood L.D., Whitaker L.L., Canman C.E., Morgan S.E., Xu Y., Barlow C., Baltimore D., Wynshaw-Boris A., Kastan M.B., Wang J.Y. Ataxia telangiectasia mutant protein activates c-Ab1 tyrosine kinase in response to ionizing radiation. Nature. 387:1997;516-519.
360. Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shilob Y., Lu K.P. Telomeric protein Pin2/TRFI as an important ATM target in response to double strand DNA breaks. J. Biol. Chem. 276:2001;29282-29291.
361. Shieh S.Y., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases chkl and cdsl (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14:2000;289-300.
362. Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:2000;1824-1827.
363. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCdsl functions as a DNA damage checkpoint in G(l) by stabilizing p53. Genes Dev. 14:2000;278-288.
364. Anderson L., Henderson C., Adachi Y. Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage. Mol. Cell. Biol. 21:2001;1719-1729.
365. Rappold I., Iwabuchi K., Date T., Chen J. Tumor suppressor p53 binding protein I (S3BP1) is involved in DNA damage-signaling pathways. J. Cell. Biol. 153:2001;613-620.
366. Post S., Weng Y.C., Cimprich K., Chen L.B., Xu Y., Lee E.Y. Phosphorylation of serines 635 and 645 of human Rad17 is cell cycle regulated and is required for G11/S checkpoint activation in response to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 98:2001;13102-13107.
367. Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ah A., Chen S.M., Abraham R.T., Wang X.F. ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses. Nature. 411:2001;969-974.
368. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., Luo G., Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J. Chk1 is an essential kinase that is regulated by ATR and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14:2000;1448-1459.
369. Zhao H., Piwnica-Worms H. Atr-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 21:2001;4129-4139.
370. Xu X., Tsvetkov L.M., Stern D.F. Chk2 activation and phosphorylation-dependent oligomerization. Mol. Cell. Biol. 22:2002;4419-4432.
371. Aprelikova O.N., Fang B.S., Meissner E.G., Cotter S., Campbell M., Kuthiala A., Bessho M., Jensen R.A., Liu E.T. BRCA1-associated growth arrest is RB-dependent. Proc. Natl. Acad. Sci. U.S.A. 96:1999;11866-11871.
372. Ouchi T., Monteiro A.N., August A., Aaronson S.A., Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2302-2306.
373. Zhang H., Somasundaram K., Peng Y., Tian H., Zhang H., Bi D., Weber B.L., EI-Deiry W.S. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 16:1998;1713-1721.
374. Ouchi T., Lee S.W., Ouchi M., Aaronson S.A., Horvath C.M. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc. Natl. Acad. Sci. U.S.A. 97:2000;5208-5213.
375. Foray N., Marot D., Randrianarison V., Venezia N.D., Picard D., Perricaudet M., Favaudon V., Jeggo P. Constitutive association of BRCA1 and c-Ab1 and its ATM-dependent disruption after irradiation. Mol. Cell. Biol. 22:2002;4020-4032.
376. Wang Q., Zhang H., Kajino K., Greene M.I. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene. 17:1998;1939-1948.
377. Li H., Lee T.H., Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promotor activity in breast cancer. J. Biol. Chem. 277:2002;20965-20973.
378. Li S., Ku C.Y., Farmer A.A., Cong Y.S., Chen C.F., Lee W.H. Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J. Biol. Chem. 273:1998;6183-6189.
379. Chen C.F., Li S., Chen Y., Chen P.L., Sharp Z.D., Lee W.H. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J. Biol. Chem. 271:1996;32863-32868.